Bayer Schering Pharma Starts New Campaign - Restore the Man

Erectile Dysfunction often comes along with Underlying Conditions / Bayer Schering Pharma is working with healthcare professionals to promote men’s health

MILAN, BERLIN, March 26, 2008 - Bayer Schering Pharma unveiled its new ‘Restore the Man’ campaign at the 23rd Annual European Association of Urology (EAU) Congress in Milan, Italy, demonstrating its commitment to providing innovative and holistic solutions that promote men’s health. ‘Restore the Man’ is about taking an integrated view of men’s health, shifting to a proactive preventive focus, and providing innovative and new therapeutic approaches to enable the successful treatment of men with a range of health problems.

"For too long, men have been blamed for not taking care of their health; but health services need to respond to men’s needs and consider a man’s overall health, not just individual conditions", said Proffessor Ian Banks, President of the European Men’s Health Forum, about the ‘Restore the Man’ campaign. "Men’s health is more than ever in the focus of the public discussion. But it needs an even more proactive approach to discuss the men specific health issues, for example at consultations for erectile dysfunction as an opportunity to explore other health problems. Where treatment is necessary, health care professionals must offer dynamic solutions that enable men of all ages to maximize their quality of life", concluded Prof Banks.

‘Restore the Man’ encourages healthcare providers, and men together with their partners, to recognize that erectile dysfunction (ED) and testosterone deficiency syndrome share common underlying conditions, such as cardiovascular disease, abdominal obesity and hypertension.(1)

Nearly 70% of men with ED have some kind of underlying condition (2). Healthcare providers should treat erectile dysfunction and check the testosterone level at the same time. It is very important to bring the testosterone level to a normal level; testosterone therapy can make this possible.

Urologists can provide an immediate solution for ED with PDE-5 inhibitors, such as Levitra®. With Nebido® and Testogel®, men’s healthcare professionals are enabled to successfully treat patients with testosterone deficiency syndrome (hypogonadism). Bayer Schering Pharma is the only company to provide such a full range of short- and long-term evidence-based treatment solutions for men with ED and testosterone deficiency.

About Bayer HealthCare Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma and as Bayer HealthCare Pharmaceuticals in the US and Canada. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. www.bayerhealthcare.com

About Bayer Schering Pharma Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, Hematology/Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. www.bayerscheringpharma.de

Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

1 Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R.Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005;174(3):827-34

2 Feldman H, Goldstein I, Hatzichristou D. Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J Urol. 1994; 151:54-61

Contact:

Yvonne Möller 
Phone: +49 30 468-17389 
Fax: +49 30 468-16710

Posted: March 2008


View comments

Hide
(web1)